Cone-Rod Dystrophy — Research Summary
Printed from RareWays (rareways.com.au) on 11 September 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Epidemiology of macular dystrophy in Japan (2011-2020): a nationwide population-based study.
Ikeda Hanako Ohashi et al. — Japanese journal of ophthalmology (3 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42690510/
- 2.
Correcting photoreceptor diseases at their source: CRISPR strategies for cone-rod dystrophy and achromatopsia.
Zaki Haniya Fatima et al. — Experimental eye research (1 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42264060/
- 3.
CDHR1-associated retinal degeneration: Clinical phenotypes and therapeutic approaches.
Narayan Akshay R et al. — Progress in retinal and eye research (1 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42562233/
- 4.
Defining a Novel RPGR Phenotype of Sector Retinitis Pigmentosa With Cone Dystrophy.
Abdalla Elsayed Maram E A et al. — Investigative ophthalmology & visual science (3 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42573183/
- 5.
Swept-Source Wide-Field OCT and OCTA (24 × 20 mm and 26 × 21 mm) in Inherited Retinal Dystrophies: First Clinical Experience with Two Novel Devices.
Farmand Ghazaleh et al. — Journal of clinical medicine (2 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42590119/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
Recruiting — Phase 1 — National Eye Institute (NEI)
https://clinicaltrials.gov/study/NCT04289571
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Cone-Rod Dystrophy
Cone-rod dystrophy is a group of inherited eye conditions that damage the light-sensing cells of the retina. The cones, which give sharp central and colour vision, are affected first, and the rods, which give night and side vision, later. Many different genes can cause it. Care focuses on low vision support, and gene-based therapies are being studied.
Most Recent Research
PURPOSE: To describe the characteristics and prevalence of macular dystrophy using a comprehensive national claims database in Japan. STUDY DESIGN: Population-based retrospective study using a nationwide claims database. METHODS: Approximately 126 million individuals covered by Japan's universal health coverage system were included. Health insurance claims from 2011 to 2020 stored in the National Database of Health Insurance Claims (NDB) of Japan were analyzed. Patients with macular dystrophy, including best vitelliform macular dystrophy (BVMD), Stargardt disease (STGD), cone/cone-rod dystrophy, or central areolar choroidal dystrophy (CACD), were identified using diagnostic codes recorded in the database. The population-based prevalence of diagnosed macular dystrophy was calculated, and age-standardized rates were derived using the WHO standard world population. RESULTS: Between 2011 and 2020, 1,268 patients with BVMD, 460 with STGD, 5758 with cone/cone-rod dystrophy, and 280 with CACD were identified in the NDB. As of October 1, 2020, the corresponding prevalence rates were 10.05, 3.65, 45.65, and 2.35 per 1,000,000 persons, respectively. CONCLUSION: This nationwide study provides updated epidemiological estimates of macular dystrophy in Japan. These findings may inform clinical management, healthcare planning, and future research on macular dystrophy.
Common Questions
What is Cone-Rod Dystrophy?
Cone-rod dystrophy is a group of inherited eye conditions that damage the light-sensing cells of the retina. The cones, which give sharp central and colour vision, are affected first, and the rods, which give night and side vision, later. Many different genes can cause it. Care focuses on low vision support, and gene-based therapies are being studied.
How many clinical trials are available for Cone-Rod Dystrophy?
RareWays currently indexes 9 clinical trials for Cone-Rod Dystrophy, of which 7 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Cone-Rod Dystrophy come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Cone-Rod Dystrophy.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.